-
1
-
-
33750008791
-
The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer
-
Daniels T.R., Delgado T., Rodriguez J.A., Helguera G., and Penichet M.L. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clinical Immunology 121 2 (2006) 144-158
-
(2006)
Clinical Immunology
, vol.121
, Issue.2
, pp. 144-158
-
-
Daniels, T.R.1
Delgado, T.2
Rodriguez, J.A.3
Helguera, G.4
Penichet, M.L.5
-
2
-
-
0033597780
-
Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family
-
Kawabata H., Yang R., Hirama T., Vuong P.T., Kawano S., Gombart A.F., and Koeffler H.P. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. The Journal of Biological Chemistry 274 30 (1999) 20826-20832
-
(1999)
The Journal of Biological Chemistry
, vol.274
, Issue.30
, pp. 20826-20832
-
-
Kawabata, H.1
Yang, R.2
Hirama, T.3
Vuong, P.T.4
Kawano, S.5
Gombart, A.F.6
Koeffler, H.P.7
-
3
-
-
0022636575
-
A transferrin receptor antibody represents one signal for the induction of IL 2 production by a human T cell line
-
Manger B., Weiss A., Hardy K.J., and Stobo J.D. A transferrin receptor antibody represents one signal for the induction of IL 2 production by a human T cell line. Journal of Immunology 136 2 (1986) 532-538
-
(1986)
Journal of Immunology
, vol.136
, Issue.2
, pp. 532-538
-
-
Manger, B.1
Weiss, A.2
Hardy, K.J.3
Stobo, J.D.4
-
4
-
-
0025362121
-
Induction of T cell activation by monoclonal antibodies specific for the transferrin receptor
-
Cano E., Pizarro A., Redondo J.M., Sanchez-Madrid F., Bernabeu C., and Fresno M. Induction of T cell activation by monoclonal antibodies specific for the transferrin receptor. European Journal of Immunology 20 4 (1990) 765-770
-
(1990)
European Journal of Immunology
, vol.20
, Issue.4
, pp. 765-770
-
-
Cano, E.1
Pizarro, A.2
Redondo, J.M.3
Sanchez-Madrid, F.4
Bernabeu, C.5
Fresno, M.6
-
5
-
-
0032959574
-
Transferrin receptor is necessary for development of erythrocytes and the nervous system
-
Levy J.E., Jin O., Fujiwara Y., Kuo F., and Andrews N.C. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nature Genetics 21 4 (1999) 396-399
-
(1999)
Nature Genetics
, vol.21
, Issue.4
, pp. 396-399
-
-
Levy, J.E.1
Jin, O.2
Fujiwara, Y.3
Kuo, F.4
Andrews, N.C.5
-
6
-
-
33750019824
-
The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells
-
Daniels T.R., Delgado T., Helguera G., and Penichet M.L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clinical Immunology 121 2 (2006) 159-176
-
(2006)
Clinical Immunology
, vol.121
, Issue.2
, pp. 159-176
-
-
Daniels, T.R.1
Delgado, T.2
Helguera, G.3
Penichet, M.L.4
-
7
-
-
0141955901
-
Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects
-
Lu Y., and Low P.S. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. Journal of Controlled Release 91 1-2 (2003) 17-29
-
(2003)
Journal of Controlled Release
, vol.91
, Issue.1-2
, pp. 17-29
-
-
Lu, Y.1
Low, P.S.2
-
8
-
-
0025005475
-
Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects
-
White S., Taetle R., Seligman P.A., Rutherford M., and Trowbridge I.S. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Research 50 19 (1990) 6295-6301
-
(1990)
Cancer Research
, vol.50
, Issue.19
, pp. 6295-6301
-
-
White, S.1
Taetle, R.2
Seligman, P.A.3
Rutherford, M.4
Trowbridge, I.S.5
-
9
-
-
0031451777
-
Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
-
Laske D.W., Youle R.J., and Oldfield E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Medicine 3 12 (1997) 1362-1368
-
(1997)
Nature Medicine
, vol.3
, Issue.12
, pp. 1362-1368
-
-
Laske, D.W.1
Youle, R.J.2
Oldfield, E.H.3
-
10
-
-
0344876636
-
Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas
-
Weaver M., and Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. Journal of Neuro-oncology 65 1 (2003) 3-13
-
(2003)
Journal of Neuro-oncology
, vol.65
, Issue.1
, pp. 3-13
-
-
Weaver, M.1
Laske, D.W.2
-
11
-
-
0029130507
-
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin
-
Chignola R., Foroni R., Franceschi A., Pasti M., Candiani C., Anselmi C., Fracasso G., Tridente G., and Colombatti M. Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin. British Journal of Cancer 72 3 (1995) 607-614
-
(1995)
British Journal of Cancer
, vol.72
, Issue.3
, pp. 607-614
-
-
Chignola, R.1
Foroni, R.2
Franceschi, A.3
Pasti, M.4
Candiani, C.5
Anselmi, C.6
Fracasso, G.7
Tridente, G.8
Colombatti, M.9
-
12
-
-
34548697576
-
Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-l-malic acid)
-
Fujita M., Lee B.S., Khazenzon N.M., Penichet M.L., Wawrowsky K.A., Patil R., Ding H., Holler E., Black K.L., and Ljubimova J.Y. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-l-malic acid). Journal of Controlled Release (2007)
-
(2007)
Journal of Controlled Release
-
-
Fujita, M.1
Lee, B.S.2
Khazenzon, N.M.3
Penichet, M.L.4
Wawrowsky, K.A.5
Patil, R.6
Ding, H.7
Holler, E.8
Black, K.L.9
Ljubimova, J.Y.10
-
13
-
-
33646137581
-
Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes
-
Chiu S.J., Liu S., Perrotti D., Marcucci G., and Lee R.J. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. Journal of Controlled Release 112 2 (2006) 199-207
-
(2006)
Journal of Controlled Release
, vol.112
, Issue.2
, pp. 199-207
-
-
Chiu, S.J.1
Liu, S.2
Perrotti, D.3
Marcucci, G.4
Lee, R.J.5
-
14
-
-
0030712969
-
Intraventricular immunotoxin therapy for leptomeningeal neoplasia
-
(discussion 1049-1051)
-
Laske D.W., Muraszko K.M., Oldfield E.H., DeVroom H.L., Sung C., Dedrick R.L., Simon T.R., Colandrea J., Copeland C., Katz D., Greenfield L., Groves E.S., Houston L.L., and Youle R.J. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 41 5 (1997) 1039-1049 (discussion 1049-1051)
-
(1997)
Neurosurgery
, vol.41
, Issue.5
, pp. 1039-1049
-
-
Laske, D.W.1
Muraszko, K.M.2
Oldfield, E.H.3
DeVroom, H.L.4
Sung, C.5
Dedrick, R.L.6
Simon, T.R.7
Colandrea, J.8
Copeland, C.9
Katz, D.10
Greenfield, L.11
Groves, E.S.12
Houston, L.L.13
Youle, R.J.14
-
15
-
-
36049031656
-
-
G.L. Mayers, J. Razeq, M.M. Abu-Hadid, Cytotoxic drug conjugates for treatment of neoplastic disease. US Patent Application No. 5,393,737. (1995).
-
-
-
-
16
-
-
0036678172
-
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells
-
Ng P.P., Dela Cruz J.S., Sorour D.N., Stinebaugh J.M., Shin S.U., Shin D.S., Morrison S.L., and Penichet M.L. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proceedings of the National Academy of Sciences of the United States of America 99 16 (2002) 10706-10711
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.16
, pp. 10706-10711
-
-
Ng, P.P.1
Dela Cruz, J.S.2
Sorour, D.N.3
Stinebaugh, J.M.4
Shin, S.U.5
Shin, D.S.6
Morrison, S.L.7
Penichet, M.L.8
-
17
-
-
0025288944
-
Avidin and streptavidin
-
Green N.M. Avidin and streptavidin. Methods in Enzymology 184 (1990) 51-67
-
(1990)
Methods in Enzymology
, vol.184
, pp. 51-67
-
-
Green, N.M.1
-
18
-
-
33750631022
-
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor
-
Ng P.P., Helguera G., Daniels T.R., Lomas S.Z., Rodriguez J.A., Schiller G., Bonavida B., Morrison S.L., and Penichet M.L. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood 108 8 (2006) 2745-2754
-
(2006)
Blood
, vol.108
, Issue.8
, pp. 2745-2754
-
-
Ng, P.P.1
Helguera, G.2
Daniels, T.R.3
Lomas, S.Z.4
Rodriguez, J.A.5
Schiller, G.6
Bonavida, B.7
Morrison, S.L.8
Penichet, M.L.9
-
19
-
-
0023243675
-
Functional expression of the human transferrin receptor cDNA in Chinese hamster ovary cells deficient in endogenous transferrin receptor
-
McGraw T.E., Greenfield L., and Maxfield F.R. Functional expression of the human transferrin receptor cDNA in Chinese hamster ovary cells deficient in endogenous transferrin receptor. The Journal of Cell Biology 105 1 (1987) 207-214
-
(1987)
The Journal of Cell Biology
, vol.105
, Issue.1
, pp. 207-214
-
-
McGraw, T.E.1
Greenfield, L.2
Maxfield, F.R.3
-
21
-
-
0019129529
-
Use of an enzyme-linked immunosorbent assay (ELISA) for screening of hybridoma antibodies against cell surface antigens
-
Suter L., Bruggen J., and Sorg C. Use of an enzyme-linked immunosorbent assay (ELISA) for screening of hybridoma antibodies against cell surface antigens. Journal of Immunological Methods 39 4 (1980) 407-411
-
(1980)
Journal of Immunological Methods
, vol.39
, Issue.4
, pp. 407-411
-
-
Suter, L.1
Bruggen, J.2
Sorg, C.3
-
23
-
-
27144550160
-
Arming antibodies: prospects and challenges for immunoconjugates
-
Wu A.M., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology 23 9 (2005) 1137-1146
-
(2005)
Nature Biotechnology
, vol.23
, Issue.9
, pp. 1137-1146
-
-
Wu, A.M.1
Senter, P.D.2
-
24
-
-
3042612638
-
Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation
-
Gosselaar P.H., van-Dijk A.J., de-Gast G.C., Polito L., Bolognesi A., Vooijs W.C., Verheul A.F., Krouwer H.G., and Marx J.J. Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation. European Journal of Clinical Investigation 32 Suppl 1 (2002) 61-69
-
(2002)
European Journal of Clinical Investigation
, vol.32
, Issue.SUPPL. 1
, pp. 61-69
-
-
Gosselaar, P.H.1
van-Dijk, A.J.2
de-Gast, G.C.3
Polito, L.4
Bolognesi, A.5
Vooijs, W.C.6
Verheul, A.F.7
Krouwer, H.G.8
Marx, J.J.9
-
25
-
-
0037064136
-
Shedding of the transferrin receptor is mediated constitutively by an integral membrane metalloprotease sensitive to tumor necrosis factor alpha protease inhibitor-2
-
Kaup M., Dassler K., Weise C., and Fuchs H. Shedding of the transferrin receptor is mediated constitutively by an integral membrane metalloprotease sensitive to tumor necrosis factor alpha protease inhibitor-2. The Journal of Biological Chemistry 277 41 (2002) 38494-38502
-
(2002)
The Journal of Biological Chemistry
, vol.277
, Issue.41
, pp. 38494-38502
-
-
Kaup, M.1
Dassler, K.2
Weise, C.3
Fuchs, H.4
-
26
-
-
0034864020
-
Phase I and II clinical trials of trastuzumab
-
Baselga J. Phase I and II clinical trials of trastuzumab. Annals of Oncology 12 Suppl 1 (2001) S49-S55
-
(2001)
Annals of Oncology
, vol.12
, Issue.SUPPL. 1
-
-
Baselga, J.1
-
27
-
-
6844250760
-
Measurement of soluble transferrin receptor in serum of healthy adults
-
Allen J., Backstrom K.R., Cooper J.A., Cooper M.C., Detwiler T.C., Essex D.W., Fritz R.P., Means Jr. R.T., Meier P.B., Pearlman S.R., Roitman-Johnson B., and Seligman P.A. Measurement of soluble transferrin receptor in serum of healthy adults. Clinical Chemistry 44 1 (1998) 35-39
-
(1998)
Clinical Chemistry
, vol.44
, Issue.1
, pp. 35-39
-
-
Allen, J.1
Backstrom, K.R.2
Cooper, J.A.3
Cooper, M.C.4
Detwiler, T.C.5
Essex, D.W.6
Fritz, R.P.7
Means Jr., R.T.8
Meier, P.B.9
Pearlman, S.R.10
Roitman-Johnson, B.11
Seligman, P.A.12
-
28
-
-
0028809381
-
Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6
-
Brooks D., Taylor C., Dos Santos B., Linden H., Houghton A., Hecht T.T., Kornfeld S., and Taetle R. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clinical Cancer Research 1 11 (1995) 1259-1265
-
(1995)
Clinical Cancer Research
, vol.1
, Issue.11
, pp. 1259-1265
-
-
Brooks, D.1
Taylor, C.2
Dos Santos, B.3
Linden, H.4
Houghton, A.5
Hecht, T.T.6
Kornfeld, S.7
Taetle, R.8
-
29
-
-
34247217546
-
Oral tolerance to contact allergens: a common occurrence? A review
-
White J.M., Goon A.T., Jowsey I.R., Basketter D.A., Mak R.K., Kimber I., and McFadden J.P. Oral tolerance to contact allergens: a common occurrence? A review. Contact Dermatitis 56 5 (2007) 247-254
-
(2007)
Contact Dermatitis
, vol.56
, Issue.5
, pp. 247-254
-
-
White, J.M.1
Goon, A.T.2
Jowsey, I.R.3
Basketter, D.A.4
Mak, R.K.5
Kimber, I.6
McFadden, J.P.7
-
30
-
-
7144235821
-
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity
-
Chinol M., Casalini P., Maggiolo M., Canevari S., Omodeo E.S., Caliceti P., Veronese F.M., Cremonesi M., Chiolerio F., Nardone E., Siccardi A.G., and Paganelli G. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. British Journal of Cancer 78 2 (1998) 189-197
-
(1998)
British Journal of Cancer
, vol.78
, Issue.2
, pp. 189-197
-
-
Chinol, M.1
Casalini, P.2
Maggiolo, M.3
Canevari, S.4
Omodeo, E.S.5
Caliceti, P.6
Veronese, F.M.7
Cremonesi, M.8
Chiolerio, F.9
Nardone, E.10
Siccardi, A.G.11
Paganelli, G.12
-
31
-
-
1642535523
-
Reducing the immune response to immunotoxin
-
Frankel A.E. Reducing the immune response to immunotoxin. Clinical Cancer Research 10 1 Pt 1 (2004) 13-15
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.1 PART 1
, pp. 13-15
-
-
Frankel, A.E.1
-
32
-
-
0023942583
-
Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6)
-
Bergamaschi G., Cazzola M., Dezza L., Savino E., Consonni L., and Lappi D. Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). British Journal of Haematology 68 3 (1988) 379-384
-
(1988)
British Journal of Haematology
, vol.68
, Issue.3
, pp. 379-384
-
-
Bergamaschi, G.1
Cazzola, M.2
Dezza, L.3
Savino, E.4
Consonni, L.5
Lappi, D.6
-
33
-
-
33745571528
-
Immunotoxin therapy of cancer
-
Pastan I., Hassan R., Fitzgerald D.J., and Kreitman R.J. Immunotoxin therapy of cancer. Nature Reviews 6 7 (2006) 559-565
-
(2006)
Nature Reviews
, vol.6
, Issue.7
, pp. 559-565
-
-
Pastan, I.1
Hassan, R.2
Fitzgerald, D.J.3
Kreitman, R.J.4
-
34
-
-
3843131713
-
Design and engineering of human forms of monoclonal antibodies
-
Penichet M.L., and Morrison S.L. Design and engineering of human forms of monoclonal antibodies. Drug Development Research 61 3 (2004) 121-136
-
(2004)
Drug Development Research
, vol.61
, Issue.3
, pp. 121-136
-
-
Penichet, M.L.1
Morrison, S.L.2
-
35
-
-
0034331218
-
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
-
Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., and Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96 9 (2000) 3102-3108
-
(2000)
Blood
, vol.96
, Issue.9
, pp. 3102-3108
-
-
Brossart, P.1
Wirths, S.2
Stuhler, G.3
Reichardt, V.L.4
Kanz, L.5
Brugger, W.6
|